-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2019, the State Drug Administration approved elamine ® (Barrettini tablets) 2 mg tablets for the treatment of moderate to severe active rheumatoid arthritis in adults.
Elamine is a tyrosine protein kinase (JAK) 1/2 inhibitor that is given orally once a day, far less than its daily dose compared to shangjie, the first oral drug of its kind already on the market in China.
and the first JAK inhibitor to go on sale was Pfizer's Tofatinib, which has dominated the market since its launch in 2012.
the potential efficacy of JAK inhibitors in multiple autoimmune areas, pharmaceutical companies are scrambling to lay out.
incomplete statistics, the world has been approved to market 7 JAK inhibitors, of which 2 are second-generation inhibitors.
also have a lot of player layout in China.
industry analysis, Elamine's biggest competitor is Shumeile and later bio-similar drugs, in 2019 Shumeile with a 59.2% decline in the success of health insurance, reduced to 1290 yuan.
price of 3998 yuan / bottle (2mg x 28 pieces), compared to Xiu Meile and other competition, Elamine's price advantage is not obvious.
is a key part of whether we can grab the market in the future.
, elamine's health care prices are "out of hiding."
, according to Sina Pharma, on January 14, Gansu Provincial Public Resources Trading Bureau issued a notice on the adjustment of the price of some drugs listed online.
the price of Lilly's Barrettini tablets was lowered from 3,998 yuan to 1,064 yuan, a drop of more than 73.3%.
adjusted price from January 20, 2021, the province's implementation, this price compared to similar competition still has a certain advantage.
, Henan Province also issued a notice to adjust the limit price of three drugs, Barrettinib tablets, doraglutide injections and fluorotratemevi inhalation powder mist agents, the adjusted price from January 13, 2021.
The global market for RA drugs will grow to $54.5 billion by 2022, making it the world's third-largest drug market after anti-tumor and diabetic drugs, according to Evaluate Pharma's Global Prescription Drug Market 2022 report.
market potential in this area is still huge.
